Welcome to the "FDA-approved" team Bimekizumab. Dr. Armstrong shows MOA of IL17a and IL17f dual inhibition, and the important PASI scores showing 2/3 of pts clear by week 16. @RheumNow #RNL2024 https://t.co/5ygHgOTfW8